VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Brucella DNA vaccine encoding chimera BLSOmp31
Vaccine Information
  • Vaccine Name: Brucella DNA vaccine encoding chimera BLSOmp31
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Vaccine Ontology ID: VO_0001144
  • Type: DNA vaccine
  • Antigen: Brucella outer membrane protein and lumazine synthase from Brucella spp. (BLS) (Cassataro et al., 2007).
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000214
  • Preparation: To develop the chimerical plasmid, the BLSOmp31 DNA sequence was amplified by PCR using pETBLSOmp31 as template and sub-cloned in the pCI-neo vector (Promega, Madison, WI). The following oligonucleotides were constructed including restriction sites at the 5
  • Virulence: None.
  • Description: Brucella outer membrane protein and lumazine synthase from Brucella spp. (BLS) induce protection against Brucella spp. A novel mode of delivering these antigens was devised as a DNA vaccine (Cassataro et al., 2007).
Host Response

Mouse Response

  • Vaccination Protocol: Mice were anaesthetized and immunized by the intramuscular route with 100 ug of pcDNABLS, pCIOmp31, pCIBLSOmp31, pcDNABLS + pCIOmp31 (100
  • Challenge Protocol: Thirty days after the last DNA injection, mice were challenged with 1 ×10^4 CFU of B. melitensis H38S or B. ovis (i.v.). Thirty days post challenge the animals were sacrificed and their spleens aseptically removed.
  • Efficacy: Vaccinationof BALB/c mice with pCIBLSOmp31 provided optimal protection level against B. ovis (3.14 log), a value significantly higher than the protection elicited by the co-delivery of two plasmids (pCIOmp31+pcDNABLS) (2.20log) or by the Rev.1 vaccine (2.42 log). Mice vaccinated with pCIOmp31 exhibited a significant protection (2.24 log) against B. ovis; pcDNABLS induced 1.94log units of protection. pCIBLSOmp31 induced significantly higher protection (1.77log) against B. melitensis than pCIOmp31 plus pcDNABLS (1.09log) and similar protection than Rev.1 (2.30 log). Mice given pCIOmp31 exhibited a significant degree of protection(1.44 log) against B. melitensis as was against B. melitensis (1.44 log), while pcDNABLS induced 1.22 log protection. Together these results show that the chimera significantly increases protection elicited against B. ovis with respect to either pcDNABLS, pCIOmp31 or Rev.1 and induces a similar degree of protection against B. melitensis infection than Rev.1 vaccination.
References
Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007 Jun 12; ; . [PubMed: 17600596].